Literature DB >> 21488095

Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study.

Wassim Chaabane1, Julien Guillotreau, Evelyne Castel-Lacanal, Sami Abu-Anz, Xavier De Boissezon, Bernard Malavaud, Philippe Marque, Jean-Pierre Sarramon, Pascal Rischmann, Xavier Game.   

Abstract

PURPOSE: The efficacy of sacral neuromodulation for treating refractory idiopathic lower urinary tract dysfunction is now well established. Nevertheless, results of this technique in neurological patients are still controversial. The aim of this retrospective study was to assess the results of sacral neuromodulation in neurogenic bladder dysfunction.
MATERIALS AND METHODS: Between 1998 and 2008, a percutaneous nerve evaluation or a two-stage technique was performed in 62 patients (mean age 50.5 ± 14.8 years) with neurogenic lower urinary tract dysfunction. Before and during the temporary stimulation, each patient had a urodynamic evaluation and performed a bladder diary. The test was considered positive if the clinical and urodynamic improvement was over 50% and if the symptoms reappeared after turning the stimulation off.
RESULTS: Lower urinary tract dysfunction was detrusor overactivity in 34 cases and chronic urinary retention in 28 cases. A detrusor-sphincter dyssynergia (DSD) was associated in nine cases. Out of the 62 patients, 41 patients (66.1%) had more than 50% improvement on urodynamic evaluation and bladder diary and 37 were implanted. With a mean follow-up of 4.3 ± 3.7 years, results remained similar to the evaluation phase in 28 cases (75.7%), were partially altered in three cases (8.1%) and lost in six cases (16.2%). In these six cases, neuromodulation failed on average 12.0 ± 12.4 months after implantation.
CONCLUSION: Sacral neuromodulation seems to constitute a serious therapeutic option for patients with neurogenic lower urinary tract dysfunction. However, its results depend on the type of the underlying neurologic disease and in particular, whether it may progress or not.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21488095     DOI: 10.1002/nau.21009

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  16 in total

Review 1.  Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Authors:  Federica Puccini; Alka Bhide; Suzy Elneil; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2015-07-09       Impact factor: 2.894

Review 2.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

Review 3.  Electrical stimulation for the treatment of lower urinary tract dysfunction after spinal cord injury.

Authors:  Meredith J McGee; Cindy L Amundsen; Warren M Grill
Journal:  J Spinal Cord Med       Date:  2015-01-13       Impact factor: 1.985

Review 4.  The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

Authors:  A Tubaro; F Puccini; C De Nunzio; G A Digesu; S Elneil; C Gobbi; V Khullar
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

5.  Understanding the dissemination of sacral neuromodulation.

Authors:  Anne M Suskind; Rodney L Dunn; Samuel R Kaufman; John O L DeLancey; J Quentin Clemens; John T Stoffel; Brent K Hollenbeck
Journal:  Surg Innov       Date:  2013-04-16       Impact factor: 2.058

6.  Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction.

Authors:  J Wöllner; J Krebs; J Pannek
Journal:  Spinal Cord       Date:  2015-07-28       Impact factor: 2.772

Review 7.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

Review 8.  [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].

Authors:  F Girtner; M Burger; R Mayr
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

9.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28

10.  Sacral Neuromodulation for Bladder Atony - A Case Report.

Authors:  Joseph Sujka; Tyler Zeoli; Joseph M Ciccone
Journal:  Urol Case Rep       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.